{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:43:52Z","timestamp":1787010232069,"version":"build-2736575974"},"reference-count":72,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2024,1,3]],"date-time":"2024-01-03T00:00:00Z","timestamp":1704240000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/ http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:p>The potential role of proprotein convertase subtilisin\/kexin type 9 (PCSK9) inhibition in the management of COVID-19 and other medical conditions has emerged as an intriguing area of research. PCSK9 is primarily known for its impact on cholesterol metabolism, but recent studies have unveiled its involvement in various physiological processes, including inflammation, immune regulation, and thrombosis. In this abstract, the authors review the rationale and potential implications of PCSK9 inhibition during the inflammatory stage of SARS-CoV-2 infection. Severe cases of COVID-19 are characterized by an uncontrolled inflammatory response, often referred to as the cytokine storm, which can lead to widespread tissue damage and organ failure. Preclinical studies suggest that PCSK9 inhibition could dampen this inflammatory cascade by reducing the production of pro-inflammatory cytokines. Additionally, PCSK9 inhibition may protect against acute respiratory distress syndrome (ARDS) through its effects on lung injury and inflammation. COVID-19 has been linked to an increased risk of cardiovascular complications, especially in patients with pre-existing cardiovascular conditions or dyslipidemia. PCSK9 inhibitors are known for their ability to lower low-density lipoprotein (LDL) cholesterol levels by enhancing the recycling of LDL receptors in the liver. By reducing LDL cholesterol, PCSK9 inhibition might protect blood vessels from further damage and lower the risk of atherosclerotic plaque formation. Moreover, PCSK9 inhibitors have shown potential antithrombotic effects in preclinical studies, making them a potential avenue to mitigate the increased risk of coagulation disorders and thrombotic events observed in COVID-19. While the potential implications of PCSK9 inhibition are promising, safety considerations and possible risks need careful evaluation. Hypocholesterolemia, drug interactions, and long-term safety are some of the key concerns that should be addressed. Clinical trials are needed to establish the efficacy and safety of PCSK9 inhibitors in COVID-19 patients and to determine the optimal timing and dosing for treatment. Future research opportunities encompass investigating the immune response, evaluating long-term safety, exploring combination therapy possibilities, and advancing personalized medicine approaches. Collaborative efforts from researchers, clinicians, and policymakers are essential to fully harness the therapeutic potential of PCSK9 inhibition and translate these findings into meaningful clinical outcomes.<\/jats:p>","DOI":"10.1097\/ms9.0000000000001601","type":"journal-article","created":{"date-parts":[[2024,1,3]],"date-time":"2024-01-03T03:00:13Z","timestamp":1704250813000},"page":"899-908","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":10,"title":["Role of PCSK9 inhibition during the inflammatory stage of SARS-COV-2: an updated review"],"prefix":"10.1097","volume":"86","author":[{"given":"Hina","family":"Arsh","sequence":"first","affiliation":[{"name":"Department of Medicine, THQ Hospital, Pasrur"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"FNU","family":"Manoj Kumar","sequence":"additional","affiliation":[{"name":"Department of Medicine, Jinnah Sindh Medical College, Karachi"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"FNU","family":"Simran","sequence":"additional","affiliation":[{"name":"Department of Medicine, Jinnah Sindh Medical College, Karachi"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sweta","family":"Tamang","sequence":"additional","affiliation":[{"name":"Department of Medicine, Nepal Medical College and Teaching Hospital, Kathmandu, Nepal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahboob ur","family":"Rehman","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Pakistan Institute of Medical Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gulfam","family":"Ahmed","sequence":"additional","affiliation":[{"name":"Department of Medicine, Muhammad Hospital, Lahore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masood","family":"Khan","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Armed Forces Institute of Cardiology, Rawalpindi, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jahanzeb","family":"Malik","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Cardiovascular Analytics Group, Islamabad"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amin","family":"Mehmoodi","sequence":"additional","affiliation":[{"name":"Department of Medicine, Ibn e Seena Hospital, Kabul, Afghanistan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,2]]},"reference":[{"key":"R1-20250806","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/S0140-6736(21)02796-3","article-title":"Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020-21","volume":"399","year":"2022","journal-title":"Lancet"},{"key":"R2-20250806","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1080\/17446651.2021.1968830","article-title":"Association of hypothyroidism with acute COVID-19: a systematic review","volume":"16","author":"Malik","year":"2021","journal-title":"Expert Rev Endocrinol Metab"},{"key":"R3-20250806","doi-asserted-by":"crossref","first-page":"e0249421","DOI":"10.1371\/journal.pone.0249421","article-title":"Thyroid function analysis in COVID-19: A retrospective study from a single center","volume":"16","author":"Malik","year":"2021","journal-title":"PLoS One"},{"key":"R4-20250806","first-page":"103856","article-title":"Effect of COVID-19 on lipid profile parameters and its correlation with acute phase reactants: a single-center retrospective analysis","volume":"78","author":"Almas","year":"2022","journal-title":"Ann Med Surg (Lond)"},{"key":"R5-20250806","first-page":"e9375","article-title":"Modern lipid management: a literature review","volume":"12","author":"Malik","year":"2020","journal-title":"Cureus"},{"key":"R6-20250806","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.jacc.2022.10.030","article-title":"PCSK9 inhibition during the inflammatory stage of SARS-CoV-2 infection","volume":"81","author":"Navarese","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"R7-20250806","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/joim.13150","article-title":"PCSK9 is associated with mortality in patients with septic shock: data from the ALBIOS study","volume":"289","author":"Vecchi\u00e9","year":"2021","journal-title":"J Intern Med"},{"key":"R8-20250806","doi-asserted-by":"crossref","first-page":"802","DOI":"10.3390\/ph15070802","article-title":"Impact of PCSK9 inhibition on proinflammatory cytokines and matrix metalloproteinases release in patients with mixed hyperlipidemia and vulnerable atherosclerotic plaque","volume":"15","author":"Basiak","year":"2022","journal-title":"Pharmaceuticals (Basel)"},{"key":"R9-20250806","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41569-018-0107-8","article-title":"PCSK9 inhibitors: clinical evidence and implementation","volume":"16","author":"Sabatine","year":"2019","journal-title":"Nat Rev Cardiol"},{"key":"R10-20250806","doi-asserted-by":"crossref","first-page":"140","DOI":"10.5603\/CJ.a2021.0148","article-title":"IMPACT of PCSK9 inhibition on clinical outcome in patients during the inflammatory stage of the SARS-COV-2 infection: Rationale and protocol of the IMPACT-SIRIO 5 study","volume":"29","author":"Kubica","year":"2022","journal-title":"Cardiol J"},{"key":"R11-20250806","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1097\/MOL.0000000000000601","article-title":"Proprotein convertase subtilisin\/kexin type 9 and lipid metabolism","volume":"30","author":"Spolitu","year":"2019","journal-title":"Curr Opin Lipidol"},{"key":"R12-20250806","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1194\/jlr.E800008-JLR200","article-title":"PCSK9 function and physiology","volume":"49","author":"Peterson","year":"2008","journal-title":"J Lipid Res"},{"key":"R13-20250806","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1194\/jlr.R026658","article-title":"The PCSK9 decade","volume":"53","author":"Lambert","year":"2012","journal-title":"J Lipid Res"},{"key":"R14-20250806","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1194\/jlr.M900273-JLR200","article-title":"A new method for measurement of total plasma PCSK9: clinical applications","volume":"51","author":"Dubuc","year":"2010","journal-title":"J Lipid Res"},{"key":"R15-20250806","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1210\/endrev\/bnab035","article-title":"The multifaceted biology of PCSK9","volume":"43","author":"Seidah","year":"2022","journal-title":"Endocr Rev"},{"key":"R16-20250806","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/MOL.0000000000000114","article-title":"PCSK9 and LDLR degradation: regulatory mechanisms in circulation and in cells","volume":"25","author":"Lagace","year":"2014","journal-title":"Curr Opin Lipidol"},{"key":"R17-20250806","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1194\/jlr.M044156","article-title":"Internalized PCSK9 dissociates from recycling LDL receptors in PCSK9-resistant SV-589 fibroblasts","volume":"55","author":"Nguyen","year":"2014","journal-title":"J Lipid Res"},{"key":"R18-20250806","doi-asserted-by":"crossref","first-page":"502","DOI":"10.34172\/apb.2020.062","article-title":"PCSK9: a key target for the treatment of cardiovascular disease (CVD)","volume":"10","author":"Sobati","year":"2020","journal-title":"Adv Pharm Bull"},{"key":"R19-20250806","doi-asserted-by":"crossref","first-page":"429","DOI":"10.7555\/JBR.29.20150052","article-title":"PCSK9 and triglyceride-rich lipoprotein metabolism","volume":"29","author":"Druce","year":"2015","journal-title":"J Biomed Res"},{"key":"R20-20250806","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1161\/CIRCULATIONAHA.118.037184","article-title":"Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk","volume":"139","author":"O\u2019Donoghue","year":"2019","journal-title":"Circulation"},{"key":"R21-20250806","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1172\/JCI8623","article-title":"The role of the LDL receptor in apolipoprotein B secretion","volume":"105","author":"Twisk","year":"2000","journal-title":"J Clin Invest"},{"key":"R22-20250806","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7555\/JBR.27.20120077","article-title":"Lipoprotein metabolism in nonalcoholic fatty liver disease","volume":"27","author":"Jiang","year":"2013","journal-title":"J Biomed Res"},{"key":"R23-20250806","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1073\/pnas.0712064105","article-title":"Molecular basis for LDL receptor recognition by PCSK9","volume":"105","author":"Kwon","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"key":"R24-20250806","doi-asserted-by":"crossref","first-page":"3345","DOI":"10.1194\/jlr.M041129","article-title":"Characterization of the role of EGF-A of low density lipoprotein receptor in PCSK9 binding","volume":"54","author":"Gu","year":"2013","journal-title":"J Lipid Res"},{"key":"R25-20250806","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2008.06.010","article-title":"Molecular basis of PCSK9 function","volume":"203","author":"Lambert","year":"2009","journal-title":"Atherosclerosis"},{"key":"R26-20250806","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1111\/j.1600-0854.2007.00562.x","article-title":"The cellular trafficking of the secretory proprotein convertase PCSK9 and its dependence on the LDLR","volume":"8","author":"Nassoury","year":"2007","journal-title":"Traffic"},{"key":"R27-20250806","doi-asserted-by":"crossref","first-page":"20502","DOI":"10.1074\/jbc.M701634200","article-title":"Effects of pH and low density lipoprotein (LDL) on PCSK9-dependent LDL receptor regulation","volume":"282","author":"Fisher","year":"2007","journal-title":"J Biol Chem"},{"key":"R28-20250806","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/j.jacc.2013.07.056","article-title":"Targeting the proprotein convertase subtilisin\/kexin type 9 for the treatment of dyslipidemia and atherosclerosis","volume":"62","author":"Urban","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"R29-20250806","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.atherosclerosis.2014.12.017","article-title":"On the function and homeostasis of PCSK9: reciprocal interaction with LDLR and additional lipid effects","volume":"238","author":"Tavori","year":"2015","journal-title":"Atherosclerosis"},{"key":"R30-20250806","doi-asserted-by":"crossref","first-page":"ITC81","DOI":"10.7326\/AITC201712050","article-title":"Dyslipidemia","volume":"167","author":"Kopin","year":"2017","journal-title":"Ann Intern Med"},{"key":"R31-20250806","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.bpa.2021.02.003","article-title":"Impact of COVID-19 infection on the cardiovascular system: an evidence-based analysis of risk factors and outcomes","volume":"35","author":"Kaye","year":"2021","journal-title":"Best Pract Res Clin Anaesthesiol"},{"key":"R32-20250806","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.clnesp.2021.07.023","article-title":"Lipid profile as an indicator of COVID-19 severity: a systematic review and meta-analysis","volume":"45","author":"Mahat","year":"2021","journal-title":"Clin Nutr ESPEN"},{"key":"R33-20250806","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.3390\/biomedicines11041206","article-title":"Atherosclerosis, cardiovascular disease, and COVID-19: a narrative review","volume":"11","author":"Vilaplana-Carnerero","year":"2023","journal-title":"Biomedicines"},{"key":"R34-20250806","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1146\/annurev-med-042220-012417","article-title":"COVID-19: inflammatory profile","volume":"73","author":"Wang","year":"2022","journal-title":"Annu Rev Med"},{"key":"R35-20250806","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s42358-020-00151-7","article-title":"Severe COVID-19: what have we learned with the immunopathogenesis?","volume":"60","author":"Bordallo","year":"2020","journal-title":"Adv Rheumatol"},{"key":"R36-20250806","doi-asserted-by":"crossref","first-page":"12047","DOI":"10.1038\/s41598-022-16357-2","article-title":"Protective effects of statins on COVID-19 risk, severity and fatal outcome: a nationwide Swedish cohort study","volume":"12","author":"Santosa","year":"2022","journal-title":"Sci Rep"},{"key":"R37-20250806","doi-asserted-by":"crossref","first-page":"2980","DOI":"10.3390\/ijerph18062980","article-title":"Access to Healthcare during COVID-19","volume":"18","author":"N\u00fa\u00f1ez","year":"2021","journal-title":"Int J Environ Res Public Health"},{"key":"R38-20250806","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1093\/ehjcvp\/pvz022","article-title":"PCSK9 and inflammation: a review of experimental and clinical evidence","volume":"5","author":"Momtazi-Borojeni","year":"2019","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"Suppl 2","key":"R39-20250806","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/2047-783X-15-S2-120","article-title":"Proinflammatory cytokines Il-6 and TNF-\u03b1 and the development of inflammation in obese subjects","volume":"15","author":"Popko","year":"2010","journal-title":"Eur J Med Res"},{"key":"R40-20250806","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1530\/REP-21-0164","article-title":"Contribution of high-fat diet-induced PCSK9 upregulation to a mouse model of PCOS is mediated partly by SREBP2","volume":"162","author":"Guo","year":"2021","journal-title":"Reproduction"},{"key":"R41-20250806","doi-asserted-by":"crossref","first-page":"251","DOI":"10.2174\/0929867328666210707192625","article-title":"PCSK 9: a link between inflammation and atherosclerosis","volume":"29","author":"Patriki","year":"2022","journal-title":"Curr Med Chem"},{"key":"R42-20250806","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.4110\/in.2019.19.e41","article-title":"A critical role of PCSK9 in mediating IL-17-producing t cell responses in hyperlipidemia","volume":"19","author":"Kim","year":"2019","journal-title":"Immune Netw"},{"key":"R43-20250806","doi-asserted-by":"crossref","first-page":"909","DOI":"10.5551\/jat.55400","article-title":"An update on the role of PCSK9 in atherosclerosis","volume":"27","author":"Yurtseven","year":"2020","journal-title":"J Atheroscler Thromb"},{"key":"R44-20250806","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMra2026131","article-title":"Cytokine storm","volume":"383","author":"Fajgenbaum","year":"2020","journal-title":"N Engl J Med"},{"key":"R45-20250806","doi-asserted-by":"crossref","first-page":"110452","DOI":"10.1016\/j.mehy.2020.110452","article-title":"Statins and PCSK9 inhibitors: what is their role in coronavirus disease 2019?","volume":"146","author":"Barkas","year":"2021","journal-title":"Med Hypotheses"},{"key":"R46-20250806","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s12985-022-01814-1","article-title":"COVID-19 infection: an overview on cytokine storm and related interventions","volume":"19","author":"Montazersaheb","year":"2022","journal-title":"Virol J"},{"key":"R47-20250806","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.3389\/fimmu.2020.01446","article-title":"The COVID-19 cytokine storm; what we know so far","volume":"11","author":"Ragab","year":"2020","journal-title":"Front Immunol"},{"key":"R48-20250806","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/AIA.0b013e318034194e","article-title":"Cytokines, inflammation, and pain","volume":"45","author":"Zhang","year":"2007","journal-title":"Int Anesthesiol Clin"},{"key":"R49-20250806","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1080\/14787210.2021.1915129","article-title":"Cytokine storm associated coagulation complications in COVID-19 patients: pathogenesis and Management","volume":"19","author":"Savla","year":"2021","journal-title":"Expert Rev Anti Infect Ther"},{"key":"R50-20250806","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1007\/s11883-022-01057-z","article-title":"Expanding biology of PCSK9: roles in atherosclerosis and beyond","volume":"24","author":"Seidah","year":"2022","journal-title":"Curr Atheroscler Rep"},{"key":"R51-20250806","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1038\/s41598-018-20425-x","article-title":"PCSK9 induces a pro-inflammatory response in macrophages","volume":"8","author":"Ricci","year":"2018","journal-title":"Sci Rep"},{"key":"R52-20250806","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.tibs.2006.12.008","article-title":"Molecular biology of PCSK9: its role in LDL metabolism","volume":"32","author":"Horton","year":"2007","journal-title":"Trends Biochem Sci"},{"key":"R53-20250806","doi-asserted-by":"crossref","first-page":"876046","DOI":"10.3389\/fmed.2022.876046","article-title":"Plasma proprotein convertase subtilisin\/kexin type 9 (PCSK9) in the acute respiratory distress syndrome","volume":"9","author":"Metkus","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"R54-20250806","doi-asserted-by":"crossref","first-page":"e000765","DOI":"10.1136\/openhrt-2017-000765","article-title":"Serum PCSK9 is modified by interleukin-6 receptor antagonism in patients with hypercholesterolaemia following non-ST-elevation myocardial infarction","volume":"5","author":"Ueland","year":"2018","journal-title":"Open Heart"},{"key":"R55-20250806","doi-asserted-by":"crossref","first-page":"6677012","DOI":"10.1155\/2021\/6677012","article-title":"Association between PCSK9 levels and markers of inflammation, oxidative stress, and endothelial dysfunction in a population of nondialysis chronic kidney disease patients","volume":"2021","author":"Dounousi","year":"2021","journal-title":"Oxid Med Cell Longev"},{"key":"R56-20250806","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1080\/1744666X.2022.2017281","article-title":"The role of PCSK9 in inflammation, immunity, and autoimmune diseases","volume":"18","author":"Frosteg\u00e5rd","year":"2022","journal-title":"Expert Rev Clin Immunol"},{"key":"R57-20250806","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.2174\/1389450123666221005092350","article-title":"COVID-19 and thrombosis: clinical aspects","volume":"23","author":"Urano","year":"2022","journal-title":"Curr Drug Targets"},{"key":"R58-20250806","first-page":"5129","article-title":"PCSK9 inhibitors suppress oxidative stress and inflammation in atherosclerotic development by promoting macrophage autophagy","volume":"15","author":"Yang","year":"2023","journal-title":"Am J Transl Res"},{"key":"R59-20250806","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1080\/13813455.2020.1788605","article-title":"Evolocumab, a PCSK9 inhibitor, protects human endothelial cells against H2O2-induced oxidative stress","volume":"128","author":"Safaeian","year":"2022","journal-title":"Arch Physiol Biochem"},{"key":"R60-20250806","doi-asserted-by":"crossref","first-page":"7092151","DOI":"10.1155\/2019\/7092151","article-title":"Vascular inflammation and oxidative stress: major triggers for cardiovascular disease","volume":"2019","author":"Steven","year":"2019","journal-title":"Oxid Med Cell Longev"},{"key":"R61-20250806","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1111\/joim.13210","article-title":"PCSK9 inhibitors for COVID-19: an opportunity to enhance the antiviral action of interferon in patients with hypercholesterolaemia","volume":"289","author":"Vuorio","year":"2021","journal-title":"J Intern Med"},{"key":"R62-20250806","doi-asserted-by":"crossref","first-page":"2972","DOI":"10.3390\/cells11192972","article-title":"PCSK9 inhibition: from current advances to evolving future","volume":"11","author":"Liu","year":"2022","journal-title":"Cells"},{"key":"R63-20250806","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.ijcard.2016.10.084","article-title":"Association of PCSK9 with platelet reactivity in patients with acute coronary syndrome treated with prasugrel or ticagrelor: The PCSK9-REACT study","volume":"227","author":"Navarese","year":"2017","journal-title":"Int J Cardiol"},{"key":"R64-20250806","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1161\/CIRCULATIONAHA.120.046290","article-title":"PCSK9 (proprotein convertase subtilisin\/kexin 9) enhances platelet activation, thrombosis, and myocardial infarct expansion by binding to platelet CD36","volume":"143","author":"Qi","year":"2021","journal-title":"Circulation"},{"key":"R65-20250806","doi-asserted-by":"crossref","first-page":"7193","DOI":"10.3390\/ijms22137193","article-title":"Proprotein convertase subtilisin kexin type 9 inhibitors reduce platelet activation modulating ox-LDL pathways","volume":"22","author":"Cammisotto","year":"2021","journal-title":"Int J Mol Sci"},{"key":"R66-20250806","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1161\/ATVBAHA.115.306032","article-title":"PCSK9 induces CD36 degradation and affects long-chain fatty acid uptake and triglyceride metabolism in adipocytes and in mouse liver","volume":"35","author":"Demers","year":"2015","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R67-20250806","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.amjcard.2014.05.060","article-title":"Effect of alirocumab, a monoclonal proprotein convertase subtilisin\/kexin 9 antibody, on lipoprotein(a) concentrations (a pooled analysis of 150 mg every two weeks dosing from phase 2 trials)","volume":"114","author":"Gaudet","year":"2014","journal-title":"Am J Cardiol"},{"key":"R68-20250806","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1161\/CIRCULATIONAHA.120.046397","article-title":"The effect of PCSK9 (proprotein convertase subtilisin\/kexin type 9) inhibition on the risk of venous thromboembolism","volume":"141","author":"Marston","year":"2020","journal-title":"Circulation"},{"key":"R69-20250806","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s12933-022-01519-3","article-title":"Association of PCSK9 with inflammation and platelet activation markers and recurrent cardiovascular risks in STEMI patients undergoing primary PCI with or without diabetes","volume":"21","author":"Song","year":"2022","journal-title":"Cardiovasc Diabetol"},{"key":"R70-20250806","doi-asserted-by":"crossref","first-page":"e0279381","DOI":"10.1371\/journal.pone.0279381","article-title":"Investigating the potential impact of PCSK9-inhibitors on mood disorders using eQTL-based Mendelian randomization","volume":"17","author":"Aman","year":"2022","journal-title":"PLoS One"},{"key":"R71-20250806","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1093\/ijnp\/pyy060","article-title":"Risk of neuropsychiatric adverse effects of lipid-lowering drugs: A Mendelian Randomization Study","volume":"21","author":"Alghamdi","year":"2018","journal-title":"Int J Neuropsychopharmacol"},{"key":"R72-20250806","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.neuron.2009.11.013","article-title":"Overexpression of low-density lipoprotein receptor in the brain markedly inhibits amyloid deposition and increases extracellular A beta clearance","volume":"64","author":"Kim","year":"2009","journal-title":"Neuron"}],"updated-by":[{"DOI":"10.1097\/ms9.0000000000002497","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000}}],"container-title":["Annals of Medicine &amp; Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MS9.0000000000001601","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T13:14:53Z","timestamp":1754486093000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MS9.0000000000001601"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,3]]},"references-count":72,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/ms9.0000000000001601","relation":{},"ISSN":["2049-0801"],"issn-type":[{"value":"2049-0801","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,3]]},"assertion":[{"value":"2023-09-16","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-11-28","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}